HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $120

Benzinga Newsdesk www.benzinga.com Positive 72.2%

Neg 0% Neu 0% Pos 72.2%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target from $110 to $120.